Efficacy analysis of neoadjuvant chemotherapy regimens in patients with HER2/neunegative locally advanced breast cancer: A nonrandomized comparative study
Journal: Kuban Scientific Medical Bulletin
Year: 2025

Background. In present times, no unified standard for selecting a neoadjuvant chemotherapy regimen for breast cancer exists. Although the efficacy of neoadjuvant chemotherapy has been confirmed by numerous clinical studies, tumor drug resistance develops in some cases, which reduces the expected effect of neoadjuvant chemotherapy. Currently, drug resistance to neoadjuvant chemotherapy is a major cause of treatment failure and one of the most challenging problems in the therapy of metastatic and